Janux Therapeutics Q3 2026 Results: Net Loss of $21.6M, Loss Narrows
Janux Therapeutics reported a net loss of $21.6 million for the third quarter of 2026, an improvement from the $24.3 million loss in the prior year period. The company maintains a strong liquidity position with $945.7 million in cash, cash equivalents, and short-term investments as of September 30, 2026.
- Key figure
- Net loss $21.6M